ReviewNature reviews. Cardiology2013
Adding a life-course perspective to cardiovascular-risk communication.
Review in Nature reviews. Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Per- and polyfluoroalkyl substances: A novel risk factor for cardiovascular disease.Ecotoxicology and environmental safety · 2026Review
- Cardiovascular Health Changes in Young Adults and Risk of Later-Life Cardiovascular Disease.JAMA network open · 2025Article
- Article
- Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.BMJ (Clinical research ed.) · 2024Article
- Assessment of Lifetime Risk for Cardiovascular Disease: Time to Move Forward.Current cardiology reviews · 2024Review
- The association of education and household income with the lifetime risk of incident atrial fibrillation: The Framingham Heart study.American journal of preventive cardiology · 2022Article
- Correlation between Coronary Artery Calcium- and Different Cardiovascular Risk Score-Based Methods for the Estimation of Vascular Age in Caucasian Patients.Journal of clinical medicine · 2022Article
- A comparison of statistical methods to predict the residual lifetime risk.European journal of epidemiology · 2022Review
- Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.Zeitschrift fur Gastroenterologie · 2022Review
- Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project.Cardiovascular diabetology · 2021Article
- Derivation of a Coronary Age Calculator Using Traditional Risk Factors and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis.Journal of the American Heart Association · 2021Observational
- A Combination of Blood Pressure and Total Cholesterol Increases the Lifetime Risk of Coronary Heart Disease Mortality: EPOCH-JAPAN.Journal of atherosclerosis and thrombosis · 2021Article
- Prevalence of the Metabolic Syndrome Among Batswana Adults in Urban and Semi-Urban Gaborone.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- A qualitative exploration of two risk calculators using video-recorded NHS health check consultations.BMC family practice · 2020Article
- Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations.Journal of molecular medicine (Berlin, Germany) · 2020Article
- Article
- Cardiovascular Disease Prevention: The Earlier the Better? A Review of Plant Sterol Metabolism and Implications of Childhood Supplementation.International journal of molecular sciences · 2019Review
- Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities).Circulation. Arrhythmia and electrophysiology · 2018Article
- Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.European journal of preventive cardiology · 2018Article
- Coronary vascular age comes of age.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current practice in the primary prevention of cardiovascular disease (CVD) involves estimation of the short-term (typically 5-10-year) risk of developing CVD. This risk estimation can serve as the prelude to a conversation between physicians and patients about CVD risk and risk-reducing therapies. However, focusing solely on short-term risk directs these conversations towards individuals who, in all likelihood, have already accrued substantial atherosclerosis during their lifetime. We suggest that estimation of lifetime risk and other novel methods of risk communication, such as risk-adjusted age, should be used as an adjunct to 10-year risk estimation. We believe that these strategies will improve patient understanding of CVD risk, identify new sections of the population who might benefit from preventive therapy, and motivate lifestyle changes and adherence to therapy early in the course of disease progression.
Indexed as
Identifiers
23296067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.